Evaluating pain relief with Maxigesic in breast cancer surgery
Analgesic Efficacy of Maxigesic Added to Opioid Based-PCA in Patients Undergoing Breast Cancer Surgery
This study tests if Maxigesic can help relieve pain safely for people aged 20 to 70 undergoing breast cancer surgery while using less opioids.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 84 (estimated) |
| Ages | 20 Years to 70 Years |
| Sex | Female |
| Sponsor | Yonsei University Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06174363 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness and safety of Maxigesic, a combination of acetaminophen and ibuprofen, as a perioperative analgesic for patients undergoing breast cancer surgery. The goal is to provide adequate pain relief while minimizing immune compromise associated with opioid use. Participants will receive Maxigesic in conjunction with opioid-based intravenous patient-controlled analgesia (IV-PCA) during their surgical procedure. The study focuses on patients aged 20 to 70 with specific health classifications undergoing cancer resection or reconstruction.
Who should consider this trial
Good fit: Ideal candidates are patients aged 20 to 70 with ASA classification 1 to 3 who are scheduled for breast cancer surgery.
Not a fit: Patients with ASA classification 4, allergies to study medications, severe liver or renal dysfunction, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved pain management and reduced opioid use in breast cancer surgery patients.
How similar studies have performed: Other studies have shown promising results with similar analgesic combinations, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancer surgery (cancer resection or reconstruction) Exclusion Criteria: * ASA classification 4/ allergy to acetaminophen, NSAIDs, opioid/ severe liver or renal dysfunction/ pregnancy
Where this trial is running
Seoul
- Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine — Seoul, South Korea (Recruiting)
Study contacts
- Study coordinator: Jin Sun Cho
- Email: chjs0214@yuhs.ac
- Phone: 82-2-2228-2419
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.